10-Q: Bakhu Holdings Reports Q1 2024 Results, Cites Ongoing Efforts to Commercialize Cannabis Technology

Bakhu Holdings, Corp. reported its financial results for the first quarter of fiscal year 2024, showing no revenue and a net loss, while continuing efforts to commercialize its licensed cannabis technology.

Summary

• Bakhu Holdings, Corp. reported no revenue for the three months ended October 31, 2023, consistent with the same period in 2022.
• The company's net loss for the quarter was $1,131,478, compared to a net loss of $3,772,653 for the same period in the previous year.
• Operating expenses totaled $1,067,367, which included $692,606 in consulting fees and $192,326 in professional fees.
• Stock-based compensation was a significant component of consulting fees, amounting to $626,975 for the quarter.
• The company's cash and cash equivalents increased to $153,263 as of October 31, 2023, from $3,101 at the end of the previous quarter.
• Bakhu is actively seeking $10 to $20 million in financing through convertible secured notes to reduce liabilities and fund operations.
• The company has an accumulated deficit of $48,610,966 as of October 31, 2023, raising concerns about its ability to continue as a going concern.
• The company is focused on commercializing its licensed cannabis technology through joint ventures, strategic partnerships, and sublicenses.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with no revenue, significant accumulated losses, and reliance on related-party financing. While there are some positive developments, such as the reduction in net loss and the settlement with VO Leasing, the overall outlook is uncertain and dependent on securing substantial additional capital.

Positives

• The net loss decreased significantly compared to the same quarter last year, from $3,772,653 to $1,131,478.
• Cash and cash equivalents increased substantially from $3,101 to $153,263 during the quarter.
• The company successfully negotiated a settlement with VO Leasing, reducing its debt and allowing the retrieval of key equipment.
• The maturity dates of significant notes payable to related parties have been extended to December 31, 2027, providing more financial flexibility.

Negatives

• The company reported no revenue for the quarter, indicating a lack of commercial activity.
• The company has an accumulated deficit of $48,610,966, raising concerns about its long-term viability.
• The company's operations are heavily reliant on related-party financing.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company is dependent on securing additional financing to continue operations and commercialize its technology.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• The company has not generated any revenue to date and is subject to risks inherent in establishing a new business.
• The company has material weaknesses in its internal controls over financial reporting.
• The company is heavily reliant on related-party financing, which may not be sustainable.
• The company's commercialization efforts may be delayed or negatively impacted by global political and economic instability, including the Ukrainian crisis and Hamas strikes in Gaza.
• The company's stock is thinly traded, and it has a negative book value, making it difficult to assign value to the conversion feature of its notes.

Future Outlook

The company expects to generate revenue through its commercialization and licensing efforts, dependent on obtaining additional capital. They are seeking $10 to $20 million through the sale of convertible secured notes to fund operations and reduce liabilities. The company anticipates that any financing will be similar to what they have received over the previous two years, consisting of short-term loans from related parties at negotiated rates of interest.

Management Comments

• Management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable.
• Management states that the company's ability to continue as a going concern is contingent upon its ability to obtain capital and ultimately achieve profitable operations.
• Management indicates that they are seeking between $10.0 and $20.0 million through the sale of convertible secured notes to reduce liabilities and to fund proposed activities.

Industry Context

The company is operating in the cannabis industry, which is subject to evolving regulations and market dynamics. The company's focus on plant cell-extraction and replication technology positions it within the growing sector of cannabis biotechnology. The company's strategy of seeking joint ventures and sublicenses is a common approach in the industry to leverage expertise and resources.

Comparison to Industry Standards

• It is difficult to directly compare Bakhu's results to industry standards due to its pre-revenue status and unique technology focus.
• Many cannabis companies are focused on cultivation, processing, and retail, while Bakhu is focused on technology licensing.
• Companies like Canopy Growth, Aurora Cannabis, and Tilray are large-scale producers with established revenue streams, unlike Bakhu.
• Biotech companies in the cannabis space, such as Amyris and Ginkgo Bioworks, are more comparable in terms of technology focus, but they have different business models and financial profiles.
• Bakhu's reliance on related-party financing is not uncommon for early-stage companies, but it does present a higher risk profile compared to companies with access to traditional capital markets.

Related Party Transactions

• The company has significant notes payable to related parties, including Cell Science Holding Ltd. and The OZ Corporation.
• The company has an Office Cost Sharing Agreement with The OZ Corporation.
• The company sold $500,000 of convertible secured notes to OZ Company as part of its financing efforts.

Stakeholder Impact

• Shareholders face significant dilution risk due to the potential issuance of new shares through convertible notes.
• Employees may be impacted by cost-cutting measures if the company fails to secure sufficient financing.
• Customers are not directly impacted at this stage as the company is pre-revenue.
• Suppliers and creditors are at risk due to the company's financial instability.
• The company's ability to repay its debts is dependent on securing additional financing.

Next Steps

• The company will continue its efforts to secure $10 to $20 million in financing through the sale of convertible secured notes.
• The company will allocate a portion of the incoming funds to repay current liabilities and operating expenses.
• The company will use the remaining funds to advance its technology customization and refinement and its licensing efforts.
• The company will continue to seek joint ventures, strategic partners, and sublicenses to commercialize its technology.

Key Dates

Keywords

cannabis, technology, bioreactor, financing, convertible notes, stock options, related party, financial results, commercialization, operating expenses